
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
TACTI-004 follows 2 clinical trials, TACTI-002 and INSIGHT-003, which also assessed efti with pembrolizumab in first-line treatment of non–small cell lung cancer (NSCLC).





























